NY-COTY
Coty Inc. announced today that Calvin Klein fragrances has achieved a Material Health Certificate at the Silver level from the Cradle to Cradle Products Innovation Institute for Calvin Klein’s first clean and environmentally conscious fragrance, CK EVERYONE Eau de toilette.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200420005792/en/
Silver level material health certification indicates that 100% of the chemical substances in CK EVERYONE Eau de toilette have been assessed and are compliant with the Cradle to Cradle Certified Product Standard material health requirements at the Silver level. These achievements also serve as the foundation of a material health optimization strategy for further improving the environmental safety of the fragrance over time.
Simona Cattaneo, President of Luxury Brands at Coty, said: “We are proud of Coty’s first Cradle to Cradle Material Health certificate for CK EVERYONE Eau de toilette which demonstrates the positive impact of our Beauty That Lasts platform. The Material Health certificate reinforces Coty’s commitment to its sustainability platform, with the objective of building a better business while making a positive contribution towards societal, ethical and environmental change within the beauty industry.”
The Cradle to Cradle Certified™ Material Health Certificate offers a solution to growing industry and consumer interest in knowing more about the chemicals used in products across their supply chains and avoiding chemicals of concern. By using the rigorous, globally recognized material health assessment methodology of the Cradle to Cradle Certified Product Standard, the Material Health Certificate provides manufacturers with a trusted means of assessing, optimizing and verifying their product chemistries for safety and the environment. The material health evaluation of CK EVERYONE Eau de toilette was executed by MBDC, a third-party Cradle to Cradle accredited assessor.
“Achieving a Cradle to Cradle Material Health certificate for CK EVERYONE Eau de toilette is another positive step in moving the beauty industry towards the universal use of materials that are safe, circular and responsible,” said Dr. Christina Raab, Vice President of Strategy and Development for the Institute. “We look forward to Coty’s continued leadership as the company uses the Cradle to Cradle Certified Product Standard as a framework for improving the sustainability of this and other products.”
“We are thrilled to collaborate with Coty on their first Material Health Certificate for CK EVERYONE Eau de toilette,” said Jay Bolus, President of MBDC. “By obtaining a Material Health Certificate, they are communicating their commitment to transparency and that their fragrance is made with healthier materials. Coty is raising the bar for the beauty industry by insisting on product quality based on Cradle to Cradle Design™.”
About the Cradle to Cradle Products Innovation Institute
The Cradle to Cradle Products Innovation Institute is dedicated to powering innovation for the circular economy through products that have a positive impact on people and planet. Through the Cradle to Cradle Certified™ Products Program, the Institute sets the global standard for products that are safe, circular and made responsibly. Cradle to Cradle Certified is used by future-focused designers, brands, retailers and manufacturers across the value chain to innovate and optimize materials and products according to the world’s most advanced science-based measures for material health, product circularity, renewable energy and climate, water and soil stewardship, and social fairness.
The Institute also powers the global shift to a circular economy through partnerships and collaborative initiatives that equip businesses, governments and other stakeholders with the technical solutions and knowledge they need to innovate the way products are designed and made.
The Institute is headquartered in Oakland, California and Amsterdam, the Netherlands with offices in Washington DC. For more information, follow @c2ccertified or visit c2ccertified.org.
About MBDC
MBDC is a firm founded in 1995 by world-renowned architect William McDonough and chemist Dr. Michael Braungart. MBDC originated the Cradle to Cradle Design™ framework and the Cradle to Cradle Certified™ Products Program. MBDC leads companies to create a world of good by assessing product designs and integrating the framework into corporate strategy, communications, operations, and supply chains. Using the process of inventory, assessment and optimization, MBDC provides unique technical expertise to develop sustainable circular economy solutions around material health, material reutilization, renewable energy use, water stewardship and social fairness. MBDC partners with clients to provide scientific assessments and spur design innovation to create a world of good.
For additional information about MBDC, please visit www.mbdc.com
About CK EVERYONE
CK EVERYONE Eau de toilette is a clean and environmentally conscious fragrance, formulated with naturally derived ingredients, naturally derived alcohol, is vegan, recyclable, and is packaged with recycled materials.
CK EVERYONE Eau de toilette is a citrus fragrance that uplifts with zesty organic orange oil, a blue tea accord, and a vibrant cedarwood base creating the perfect combination of clean freshness, sweet sensuality and provocative edge. Master perfumer and creator of the original CK ONE fragrance, Alberto Morillas crafted the clean and genderless fragrance exuding freshness using 77% of naturally derived ingredients.
The CK EVERYONE bottle and packaging were created from recycled materials to honor its purity and simplicity. The ultra-modern transparent glass bottle contains 10% of post-consumer recycled materials and is recyclable with the removal of the pump and the elastic while the folding carton contains 30% of post-consumer recycled materials.
CK EVERYONE is available globally in a 50ml, 100ml, and 200ml, Eau de toilette spray.
About Coty Inc.
Coty is one of the world’s largest beauty companies with an iconic portfolio of brands across fragrance, color cosmetics, hair color and styling, and skin and body care. Coty is the global leader in fragrance, a strong number two in professional hair color & styling, and number three in color cosmetics. Coty’s products are sold in over 150 countries around the world. Coty and its brands are committed to a range of social causes as well as seeking to minimize its impact on the environment.
For additional information about Coty Inc., please visit www.Coty.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200420005792/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
